UNSPSC 51313209: Pirdonium

This classification denotes a histamine-1 receptor antagonist with the molecular formula C22H30NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QLE9A8YF1U, chemically known as 1,1-dimethyl-2-(((p-methyl-alpha-phenylbenzyl)oxy)methyl)piperidinium but generally known as pirdonium, which bears US NIH Compound Identifier 3047852. European Medicines Agency schedules Pirdonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09901MIG.

The term PIRDONIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). As of Q4 2014, PIRDONIUM remains the US FDA Preferred Term for this commodity. Pirdonium bears US NLM identifiers UMLS ID C2981353 and NCI Concept Code C87747. SMILES: CC1=CC=C(C=C1)C(C2=CC=CC=C2)OCC3CCCC[N+]3(C)C.

UNSPSC 51313209 Pirdonium is a Commodity code under which state and local governments procure pharmaceutical products, medical supplies, and health-related items for public health programs, emergency response, and institutional healthcare delivery. Recent activity shows solicitations for naloxone and drug deactivation systems for community health initiatives, generic pharmaceuticals and over-the-counter products distributed through state cooperative purchasing alliances, and exploratory direct-to-manufacturer pharmacy benefit programs. The scope spans procurement of finished pharmaceutical products with specific National Drug Codes, medical devices supporting harm reduction and public safety, and bulk OTC supplies for state and local health systems. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing authorities coordinating across multiple jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and participating states).

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted Request for Information HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, with a response deadline of April 3, 2026. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. All three solicitations require vendors to meet FDA compliance, maintain specific insurance coverages including commercial general liability, and certify drug supply chain security and good manufacturing practices where applicable.